Sarepta falls as article questions eteplirsen study

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Shares of Sarepta Therapeutics (SRPT -7.1%) are down sharply in morning trading.

The catalyst for the move looks to be an article by SA contributor EnhydrisPECorp who, according to the disclosure statements, was long SRPT last month and is now short.

Essentially, the piece attacks the small sample size of the eteplirsen Phase 2 trial and questions if it was appropriate (from a statistical perspective) to deem two patients outliers for the purpose of evaluating ambulatory performance even though they demonstrated "dramatic increases in dystrophin production."

Incidentally, SA contributor Steven Breazzano also published a bearish piece on SRPT today.